An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies

International Journal of Radiation Oncology Biology Physics

Volumn 43, Issue 5, 1999, Pages 1001-1008

  Tishler, Roy B ^a,b   Busse, Paul M ^a,b   Norris Jr , Charles M ^b,c   Rossi, René́ ^b,c   Poulin, Mark ^b,c   Thornhill, Lee ^b   Costello, Rosemary ^b   Peters, Edward S ^b   Colevas, A Dimitrios ^b   Posner, Marshall R ^b  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Combined modality therapy; Head and neck; Paclitaxel; Radiation

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEAD CANCER; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; NECK CANCER; PRIORITY JOURNAL; TOXICITY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; TREATMENT FAILURE;

EID: 0032943237     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00533-1     Document Type: Article

References (35)

1. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 77:1980;1561-1565.
2. Catimel G., Verweij J., Mattijssen V., et al. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol. 5:1994;533-537.
3. Dreyfuss A.I., Clark J.R., Norris C.M., et al. A Phase II trial of docetaxel in squamous cell cancer of the head and neck. J Clin Oncol. 14:1996;1672-1678.
4. Forastiere A.A., Leong T., Murphy B., et al. A Phase II trial of high-dose paclitaxel + cisplatin + G-CSF versus low-dose paclitaxel + cisplatin in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group Trial. Proc ASCO. 16:1997;384a.
5. Forastiere A.A., Neuberg D., Taylor S.G. IV, et al. Phase II evaluation of taxol in advanced head and neck cancer: An Eastern Cooperative Oncology Group Trial. Monogr Natl Cancer Inst. 5:1993;181-184.
6. Forastiere A.A. Use of paclitaxel (TAXOL) in squamous cell carcinomas of the head and neck. Semin Oncol. 20:1993;56-60.
7. Forastiere A.A. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol. 21:1994;49-52.
8. Tishler R.B., Geard C.R., Hall E.J., et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 52:1992;3495-3497.
9. Tishler R.B., Schiff P.B., Geard C.R., et al. Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 22:1992;613-617.
10. Liebman J.E., Cook J.A., Fisher J., et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 86:1994;441-446.
11. Leonard C.E., Chan D.C., Chou T.-C., et al. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head an neck. Cancer Res. 56:1996;5198-5204.
12. Milas L., Hunter N.R., Mason K.A., et al. Enhancement of tumor radioresponse of a murine mammary carcinoma by Taxol. Cancer Res. 54:1994;3506-3510.
13. Milas L., Hunter N.R., Mason K.A., et al. Role of reoxygenation in induction of enhancement of tumor response by paclitaxel. Cancer Res. 55:1995;3564-3568.
14. Clark J., Busse P., Norris C. Jr, et al. Induction chemotherapy with cisplatin, fluorouracil and high dose leucovorin (PFL) for squamous cell carcinoma of the head and neck long term results . J Clin Oncol. 15:1997;3100-3110.
15. Dreyfus A.I., Clark J.R., Wright J.E., et al. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated Stage IV carcinoma of the head and neck. Ann Intern Med. 112:1990;167-172.
16. Ensley J.F., Jacobs J.R., Weaver A., et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer. 54:1984;811-814.
17. Glicksman A.S., Slotman G., Doolittle C. III, et al. Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 30:1994;1043-1050.
18. Merlano M., Vitale V., Rosso R., et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med. 327:1992;1115-1121.
19. Browman G.P., Cripps C., Hodson D.I., et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol. 12:1994;2648-2653.
20. Adelstein D.J., Kalish L.A., Adams G.L., et al. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: An Eastern Oncology Cooperative Group Pilot Study. J Clin Oncol. 11:1993;2136-2142.
21. Hall E.J. Radiobiology for the radiologist. 1994;JB Lippincott Co, Philadelphia.
22. Cook J, Teague D, DeGraff W; et al. Paclitaxel radiosensitization correlates with G2/M accumulation and depletion of late S-phase cells. Proceedings of the 9th International Conference on Chemical Methods of Cancer Treatment. Christ Church, Oxford, UK, 1995.
23. Joschko M.A., Webster L.K., Groves J., et al. Radiation enhancement by taxol in squamous carcinoma of the hypopharynx (FaDu) in nude mice. Proc Am Assoc Cancer Res. 35:1994;674.
24. Lowe S.W., Ruley H.W., Jacks T., et al. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
25. Lowe S.W., Bodis S., McClatchey A., et al. p53 Status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
26. Wahl A.F., Donaldson K.L., Fairchild C., et al. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Med. 2:1996;72-79.
27. Huinzing M.T., Keung A.C.F., Rosing H., et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 11:1993;2127-2135.
28. Choy H., Akerley W., Safran H., et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol. 12:1994;2682-2686.
29. Glantz M.J., Choy H., Kearns C.M., et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol. 14:1996;600-609.
30. Plasswilm L., Kisschner M., Sauer R. Concurrent Taxol and split-course accelerated radiotherapy for advanced head and neck cancer. Strahlenther Onkol. 172:1996;573-579.
31. Hoffmann W., Belka C., Schimdberger H., et al. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer-results from a Phase I trial. Int J Radiat Oncol Biol Phys. 38:1997;691-696.
32. Steinberg L., Hassan M., Olmsted L., et al. A Phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma. Semin Oncol. 24:1997;51-56.
33. Rosenthal D.I., Sinard R.J., Ofubuki O., et al. Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: A Phase I study. Semin Oncol. 24:1997;67-71.
34. Wiernik P.H., Schwartz E.L., Strauman J.J., et al. Phase I clinical and pharmacokinetic study of Taxol. Cancer Res. 47:1987;2486-2493.
35. Rowinsky E.K., Onetto N., Canetta R.M., et al. Taxol: The first of the Taxanes, an important new class of antitumor agents. Semin Oncol. 19:1992;646-662.